Immunogenicity of Influenza Vaccine in Long Term Care

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-10-31

Study Completion Date

2021-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is designed to evaluated if adjuvanted vaccine elicits higher T cell and B cell responses than non-adjuvanted standard dose influenza vaccine in nursing home residents.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Adjuvanted Influenza Vaccination Year 2 Follow-On Survey

NCT03599739

Influenza Influenza-like Illness Influenza, Human

COMPLETED

High-Dose Influenza Vaccine in Nursing Homes

NCT01815268

Influenza

UNKNOWN PHASE4

Adjuvanted Influenza Vaccination in U.S. Nursing Homes

NCT02882100

Influenza Influenza-like Illness

COMPLETED PHASE4

Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Elderly Subjects

NCT00329927

Influenza

COMPLETED PHASE2

Immune Response to High-Dose vs. Standard Dose Influenza Vaccine

NCT02297542

Elderly Immune System

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Summary: Study investigators will recruit residents of nursing homes that are administering a licensed influenza vaccine as their standard or care, either the trivalent influenza vaccine (Fluvirin) or the adjuvanted trivalent influenza vaccine (Fluad). Eligible residents are those or their legally authorized representatives who give written, informed consent for three blood draws over one month's time and permission to review their nursing home medical and administrative records, including information required to be submitted to Medicare including quality performance data (the Minimum Dataset or MDS) and Medicare claims data for demographic and underlying disease comparisons between our participating populations between nursing homes. The investigators propose to study up to 230 subjects in one season at a 1:1 ratio of adjuvanted vs. and non-adjuvanted vaccine.

Background: Influenza is the most common clinically important viral infection of older adults. Influenza vaccination is associated with reduced hospitalization, strokes, heart attacks and death in non-institutional older adult populations, but the benefit of influenza vaccine for the oldest population has been questioned. The adjuvanted vaccine was shown in the past to elicit higher antibody titers than non-adjuvanted TIV. This included the elderly population as well. There are far more limited data about cell-mediated immunity (CMI) and use of the adjuvanted vaccine. There are data that support that CMI is important beyond the helper function to B cells. CMI helps mitigate influenza disease if the antibodies alone are not adequately protective.

Objectives: To determine if adjuvanted vaccine elicits higher T cell and B cell responses than non-adjuvanted standard dose influenza vaccine in nursing home residents.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Blood draw- adjuvanted TIV

individuals who received adjuvanted trivalent influenza vaccine (aTIV, Fluad) and consent to a blood draw

Group Type EXPERIMENTAL

Blood Draw

Intervention Type PROCEDURE

Sampling 3 blood draws Day 0 for humoral and CMI 30 ml prior to vaccination (up to 2 week prior to vaccination) Day 7 for CMI 20 ml (+/- 1 day) Day 28 for humoral 10 ml (+/- 3 days)

Blood draw - nonadjuvanted TIV

individuals who received nonadjuvanted trivalent influenza vaccine and consent to a blood draw

Group Type ACTIVE_COMPARATOR

Blood Draw

Intervention Type PROCEDURE

Sampling 3 blood draws Day 0 for humoral and CMI 30 ml prior to vaccination (up to 2 week prior to vaccination) Day 7 for CMI 20 ml (+/- 1 day) Day 28 for humoral 10 ml (+/- 3 days)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood Draw

Sampling 3 blood draws Day 0 for humoral and CMI 30 ml prior to vaccination (up to 2 week prior to vaccination) Day 7 for CMI 20 ml (+/- 1 day) Day 28 for humoral 10 ml (+/- 3 days)

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Resident of Medicare Certified Facility (so they have to report Minimum Data Set (MDS) data)
* Residence in a long-term care facility administering a Seqirus influenza vaccine as the standard-of-care.
* Agreed to receive the vaccine that the NH plans to give to them
* \>= 65 years old
* Able to obtain consent from subject or legally authorized representative (LAR) and assent from subject
* Able to participate throughout the study period
* Resident for at least 45 days prior to enrollment

Exclusion Criteria

* Recent illness (within 30 days) severe enough to require hospitalization or physician-directed outpatient pharmacotherapy
* Receiving chemotherapy for an active cancer

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No